Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
NYSE:PFE
Pfizer Inc (PFE)
26.17
+0.57 (2.23%)
as of Jun 11, 2026, 8:00:00 pm Market Open.
322 watching
Financials 
Technical Analysis 0
BUY
4% dividend yield. Trades had about 11 X earnings. They should continue to do well.
Paul Harris, CFAOwned
biotechnologypharmaceutical
BUY
Uses a two-pronged approach. Teva (TEVA-Q) is his growth drug stock and Pfizer (PFE-N) is his value drug stock. Thinks the tide has turned for this stock. Just won the Lipitor patent case giving them patent protection through to 2011. Have upped their dividend.
Norman LevineOwned
biotechnologypharmaceutical
BUY
Big pharmaceuticals have just been decimated this year. This one just won a major patent challenge in the last few days, so the sentiment has turned a bit. It will take some time for these stocks to give the kind of return that we were used to. Still phenomenally profitable. Very cheap, trading at 11 X earnings. Good dividend.
Laura WallaceOwned
biotechnologypharmaceutical
TOP PICK
He has a 2-pronged approach to the pharmaceutical area. Has a growth segment through Teva (TEVA-Q) and this one is his value play. Dividend is now about 4.5%. It’s selling at about 12/13 X next year’s earnings. Have a great pipeline coming along.
Norman LevineOwned
biotechnologypharmaceutical
BUY
The world seems to hate the large US phamaceuticals right now, but the valuation now is better than he has ever seen it. They generate good cash and can buy a bit of a pipeline if they have to.
John ZechnerOwned
biotechnologypharmaceutical
BUY
The largest pharmaceutical company in the world. Have a good pipeline of drugs. Well-managed.
Don ReedOwned
biotechnologypharmaceutical
TOP PICK
Owns this in tandem with Teva (TEVA-Q). This is their value company. Have had a lot of problems but feels this is already in the stock. Selling at about 10 or 11 X next year's earnings. Yield about 3.5%. Expect there will be an nice kick out of the stock when some of the problems are settled.
Norman LevineOwned
biotechnologypharmaceutical
BUY
The pharmaceutical area has been very difficult for a long time. They face an FDA which has been very difficult. Cheap from a historical point of view. Throw up tons of free cash flow. P/E is in the range of 10/12 X. It's a long road ahead for them. Thinks Pfizer's pipeline is being under valued. Bad news is already built into the stock.
Paul Harris, CFAOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Sept 7/05. Down 18%.) His model is still showing a 50% upside. Still likes.
Brian Acker, CAOwned
biotechnologypharmaceutical
BUY
There are law suits coming at these companies from different directions. Merck (MRK-N) just got hit with a massive lawsuit in Texas and this has put a big pall over the industry. However, the demograpohics in this industry are fabulous. This one is the biggest in the industry and they have a huge amount of cash on their balance sheet. The options are very cheap and not a bad way to go.
biotechnologypharmaceutical
DON'T BUY
Not a fan of the big drug companies. They are under tremendous pressure. One of the biggest expenses the US has to grapple with is health care, so the government is now on the side of the consumer, so it would be very hard for big pharma to have the kind of margins and sales growth they used to have.
biotechnologypharmaceutical
BUY
The overall pharmaceutical industry has had a tough time. Yields almost 4%. Trading at close to 10 X earnings. This industry has had bad direction from the FDA. Great balance sheet and lots of free cash flow.
Paul Harris, CFAOwned
biotechnologypharmaceutical
WAIT
There's a possibility for it to go to $19.65 at which time he will buy more. It's in a bottoming process. Looking for the new earnings estimates to come in during the next few weeks. His model price is $36 which is a 51% differential.
Brian Acker, CAOwned
biotechnologypharmaceutical
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
